Brower Piven Encourages Investors Who Have Losses in Excess of $100,000 From Investment in AEterna Zentaris Inc. to Inquire A...
June 25 2012 - 1:57PM
Brower Piven, A Professional Corporation announces that a class
action lawsuit has been commenced in the United States District
Court for the Southern District of New York on behalf of purchasers
who purchased the securities of AEterna Zentaris Inc. ("AEterna" or
the "Company") (Nasdaq:AEZS) during the period between February 3,
2010 and April 1, 2012, inclusive (the "Class Period").
If you have suffered a net loss for all transactions in AEterna
Zentaris Inc. securities during the Class Period, you may obtain
additional information about this lawsuit and your ability to
become a lead plaintiff by contacting Brower Piven at
www.browerpiven.com, by email at hoffman@browerpiven.com, by
calling 410/415-6616, or at Brower Piven, A Professional
Corporation, 1925 Old Valley Road, Stevenson, Maryland 21153.
Attorneys at Brower Piven have combined experience litigating
securities and class action cases of over 60 years.
No class has yet been certified in the above action.
Members of the Class will be represented by the lead plaintiff and
counsel chosen by the lead plaintiff. If you wish to choose
counsel to represent you and the Class, you must apply to be
appointed lead plaintiff no later than August 14, 2012 and be
selected by the Court. The lead plaintiff will direct the
litigation and participate in important decisions including whether
to accept a settlement and how much of a settlement to accept for
the Class in the action. The lead plaintiff will be selected from
among applicants claiming the largest loss from investment in the
Company during the Class Period. You are not required to have
sold your shares to seek damages or to serve as a Lead
Plaintiff.
The complaint accuses the defendants of violations of the
Securities Exchange Act of 1934 by virtue of the Company's failure
to disclose during the Class Period accurate information about the
prospects of perifosine, its development-stage colon cancer
drug. According to the complaint, after, on April 2, 2012,
the Company announced that phase 3 clinical trials showed
that perifosine administered with capecitabine was no more
effective than capecitabine administered with a placebo in patients
with refractory advanced colorectal cancer, the value of AEterna
shares declined significantly.
If you choose to retain counsel, you may retain Brower Piven
without financial obligation or cost to you, or you may retain
other counsel of your choice. You need take no action at this
time to be a member of the class.
CONTACT: Charles J. Piven
Brower Piven, A Professional Corporation
Stevenson, Maryland
410/415-6616
hoffman@browerpiven.com
Aeterna Zentaris (NASDAQ:AEZS)
Historical Stock Chart
From Jun 2024 to Jul 2024
Aeterna Zentaris (NASDAQ:AEZS)
Historical Stock Chart
From Jul 2023 to Jul 2024